Oncolytics Biotech Inc T.ONC

"The reality is the boats are shaking"

[Noteable]

 "The reality is the boats are shaking," Cowen analyst Yaron Werber tells Axios.

• As the financing market improves and federal interest rates stabilize, "there's a confluence of pharma sitting on dry powder while biotech (companies) have become willing sellers," Werber says.
• "We don't expect M&A to slow down, especially given there are plenty of cheap smidcap biotechs with commercial/late-stage assets of interest to pharma," Jefferies analyst Michael Yee wrote in a recent note.

https://www.axios.com/2023/12/28/biopharma-biotech-merger-deal-2023-2024

[Noteable]

Analysts upbeat on biopharma M&A activity in 2024 According to PwC, the M&A activity in the pharmaceutical and life sciences sector could continue humming in 2024. Despite a challenging interest rate environment, PwC projects the sector to see deal values ranging from $225 billion to $275 billion. Deal volume in 2023 was in line with pre-pandemic levels.  Leerink also

[Noteable]

Oncology was the top therapeutic area by deal value in 2023 with $49B across 11 deals.  This effectively translated into an avereage value of $4.45 Billion per deal.

[Noteable]

January 04, 2024 - Big Pharma Seeking Pipeline Diversity: Big Pharma companies are grappling with an internal research and development deficit, limiting their capacity for replenishment in the face of the patent cliff. To offset the revenue loss, these companies are actively seeking "best-in-portfolio" deals across both late- and early-stage assets. Areas such as rare diseases

[Noteable]

Areas such as rare diseases, oncology, and immunology are particularly appealing, with investments in drugs nearing regulatory approval offering a more expedited and certain path to market. McKinsey reports an increasing percentage of revenue derived from externally sourced pharmaceutical innovation, emphasizing the significance of such deals.    Looking ahead, it is anticipated that

[Noteable]

As previously posted the FDA had granted Ipen's NALIRIFOX treatment regimen a PDU date of February 14, 2024  whereby the FDA will review of Ipsen’s sNDA application for the company's Onivyde regimen (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) - as a first-line combination treatment for mPDAC.  Onivyde is

[Noteable]

So it could well be that both ONCY and PANCAN are awaiting the FDA's Feburary 14, 2024 PDU on Ipen's sNDA with the Onivyde regimen in first line mPDAC patients before moving forward with pelareorep + the immune checkpoint inhibitor Tecentriq + chemotherapy in a Phase 3 (post approval /confirmatory) trial in first-line mPDAC patients.  ONCY's / PanCan's Phase 2

[Noteable]

In early 2022, and pursuant to Ipen's initial approval of Onivyde in 2015, as a 2nd line treatment in mPDAC, Biden signed into law the IRA which determined that in drug development, biologics will be favored over small-molecule drugs because they have an extra four years of protection against price negotiations. While small molecule drugs will come up for negation nine

[Noteable]

Things are happening.

[lonc17]

Hi Noteable, Care to elaborate a bit?  And can you let me know what it is you are seeing on the Flames link? Thanks. 

[Noteable]

I already have "elaborated".

[venture009]

Notable, do you think he may be prepared to put a large amount of money into ONC and how will the market react to such news?

[lonc17]

Still not seeing it, Noteable.  Should I also post a link to the bios of some very rich guys and suggest some connection with ONC? What's the point of your post?

[fox7mf]

N. M. Edward's? His net worth is in & around $3b. Buying Oncy will tap him out!;)

[venture009]

It's not Edwards, it's most likely Alvin Libin. He has been a huge supporter of medical research in Calgary, contributing massive amounts of money to medical research. If this is the reason for ONC advertising on TV then what are we getting in return. Hopefully ONC will release something of substance soon to elevate the share price because what they have provided recently doesn't come

[2O2Ovision]

If we're going to pick favorites I'll go with the Riddell Family (albeait former co-owners). Their latest quest is to raise 250M for a local cancer centre and just donated another 25M before chrismas for ongoin CAR-t research here in Calgary. No shortage of local money in town and maybe some day one of these billionaires/foundations will hear about ONC.

[Noteable]

So the reality is the boats are shaking.

[Noteable]

FDA's Accelerated Approval process for innovative and novel drugs to treat rare and orphan diseases has moved in the direction of granting Accelerated Approval prior to having a Phase 3 clinical study in place and fully enrolled.  Comment on this Post

[Noteable]

The reality is, most companies that are eligible for buyouts are in the earlier stage. Lilly doesn’t mind the risk of taking on an early-stage company and just has to be better than its competitors at predicting what’s going to be the next big thing in medicine.  “If someone had like a platform or like a really strong pipeline that we could add value to, I don't think the number next to

[Noteable]

January 09, 2024 - JPM 24 - Merck wants to beef up its immunology pipeline through additional deals, the Big Pharma’s chief medical officer Eliav Barr said at an Endpoints News event on Tuesday.   “We’ll be looking for those immunology opportunities that we think can complement or add a new facet to things,” Barr said. In April 2023 Merck acquired the precision medicine Phase 2